Last reviewed · How we verify
Gastrodia and Uncaria granule
Gastrodia and Uncaria granule is a Small molecule drug developed by Shanghai Institute of Hypertension. It is currently FDA-approved.
At a glance
| Generic name | Gastrodia and Uncaria granule |
|---|---|
| Sponsor | Shanghai Institute of Hypertension |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gastrodia and Uncaria granule CI brief — competitive landscape report
- Gastrodia and Uncaria granule updates RSS · CI watch RSS
- Shanghai Institute of Hypertension portfolio CI
Frequently asked questions about Gastrodia and Uncaria granule
What is Gastrodia and Uncaria granule?
Gastrodia and Uncaria granule is a Small molecule drug developed by Shanghai Institute of Hypertension.
Who makes Gastrodia and Uncaria granule?
Gastrodia and Uncaria granule is developed and marketed by Shanghai Institute of Hypertension (see full Shanghai Institute of Hypertension pipeline at /company/shanghai-institute-of-hypertension).
What development phase is Gastrodia and Uncaria granule in?
Gastrodia and Uncaria granule is FDA-approved (marketed).